Propanc Biopharma (PPCB) Short-Term Debt issuances (2013 - 2014)
Propanc Biopharma (PPCB) posted quarterly Short-Term Debt issuances of -$1.0 for Q2 2014, up 98.96% year-over-year from -$0.5 in Q2 2013, and down 200.0% quarter-over-quarter from $1.0 in Q4 2013.
Propanc Biopharma (PPCB) Short-Term Debt issuances (2013 - 2014) Analysis & Trends
Propanc Biopharma (PPCB) has reported Short-Term Debt issuances for 2 consecutive years, with -$1.0 the latest figure, recorded in Q2 2014.
- In Q2 2014, Short-Term Debt issuances rose 98.96% year-over-year to -$1.0; the TTM figure through Mar 2015 stood at -$1.0 (up 99.01% YoY), while the FY2014 annual figure was -$6.0, down 220.0% from the prior year.
- Short-Term Debt issuances slipped to -$1.0 in Q2 2014 per PPCB's latest filing, from $1.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $1.0 in Q4 2013 and bottomed at -$96.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | -1.00 |
| Jun 30, 2014 | -1.00 |
| Dec 31, 2013 | 1.00 |
| Dec 31, 2013 | 1.00 |
| Sep 30, 2013 | -6.00 |
| Sep 30, 2013 | -6.00 |
| Jun 30, 2013 | -96.00 |
| Jun 30, 2013 | -96.00 |